Karyopharm Therapeutics announced a 20% workforce reduction, citing limited success in securing strategic alternatives to sustain operations. The company faces financial strain with a $1.6 billion accumulated deficit and declining sales of its multiple myeloma drug Xpovio. Its sole investigational candidate, eltanexor, demonstrated a 31% response rate in mid-stage trials but has yet to advance to approval. Karyopharm continues exploring mergers, financing, and restructuring strategies amid operational and market pressures.